The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy
Keyword(s):
Keyword(s):
2017 ◽
Vol 119
(1)
◽
pp. 967-972
◽
Keyword(s):
2019 ◽
Vol 83
(5)
◽
pp. 809-815
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2019 ◽
Vol 111
◽
pp. 835-840
◽
Keyword(s):
2020 ◽
Keyword(s):